Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer

Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer

The early-stage diagnosis of papillary thyroid cancer (PTC) has significantly increased in incidence worldwide without any beneficial impact on survival. In order to improve the risk assessment in PTC, we have conducted a retrospective study in which we analyzed the BRAF V600E mutation and CPSF2 pro...

Full description

Bibliographic Details
Main Authors:	Irena Ivković, Zgjim Limani, Antonia Jakovčević, Srećko Gajović, Sven Seiwerth, Ana Đanić Hadžibegović, Drago Prgomet
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Series:	Biomedicines
Subjects:	papillary thyroid cancer metastases CPSF2 BRAF V600E mutation recurrence
Online Access:	https://www.mdpi.com/2227-9059/11/1/53

Similar Items

Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
by: Siraj M. Ali, et al.
Published: (2014-05-01)

Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma
by: Changjiao Yan, et al.
Published: (2019-07-01)

Beneficial effects of vemurafenib on craniopharyngioma carrying BRAF-V600E mutation
by: WANG Xi, YE Ting, NIE Min, WU Xueyan, MAO Jiangfeng
Published: (2024-06-01)

Clinical response to dabrafenib plus trametinib in BRAF V600E mutated papillary craniopharyngiomas: a case report and literature review
by: Paul Hanona, et al.
Published: (2024-11-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
by: Eva Marie Erfurth, et al.
Published: (2024-12-01)

Association of BRAF V600E immunoexpression with clinicopathological variant groups in papillary thyroid carcinoma
by: Hung Nguyen Van, et al.
Published: (2022-12-01)

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
by: Jennifer A. Silver, et al.
Published: (2021-11-01)

BRAF gene mutation (V600E) in aspiration cytology of patients with suspected papillary thyroid carcinoma
by: Mohammadhossein Dadgarnia, et al.
Published: (2021-10-01)

MRI-Based Texture Analysis for Preoperative Prediction of BRAF V600E Mutation in Papillary Thyroid Carcinoma
by: Zheng T, et al.
Published: (2023-01-01)

Association of <i>BRAF</i> V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer
by: Ivan Blazekovic, et al.
Published: (2024-02-01)

BRAF V600E potentially determines “Oncological Resectability” for “Technically Resectable” colorectal liver metastases
by: Shin Kobayashi, et al.
Published: (2021-10-01)

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China
by: Meiling Huang, et al.
Published: (2019-07-01)

Predicting factors of central lymph node metastasis and BRAF V600E mutation in Chinese population with papillary thyroid carcinoma
by: Sheng Li Zhou, et al.
Published: (2021-07-01)

BRAFV600E mutation, BRAF-activated long non-coding RNA and miR-9 expression in papillary thyroid carcinoma, and their association with clinicopathological features
by: Chenlei Shi, et al.
Published: (2020-06-01)

A Case of Concomitant Lung Adenocarcinoma and Pleural Metastasis of Papillary Thyroid Carcinoma With BRAF V600E Mutation
by: Akinari Atsumi, et al.
Published: (2025-02-01)

Določanje mutacije V600E v genu BRAF
by: Petra Škerl, et al.
Published: (2010-12-01)

BRAF V600E and lymph node metastases in papillary thyroid cancer
by: Pan Chen, et al.
Published: (2020-10-01)

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
by: Morena Fasano, et al.
Published: (2022-01-01)

Digital Papillary Adenocarcinoma: The Detection of Low-Risk Human Papillomaviruses and the <i>BRAF</i> p.V600E Mutation in a Subset of Cases
by: Feifan Chen, et al.
Published: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
by: Ariane Fizazi, et al.
Published: (2024-11-01)

Comparative study between Immunohistochemistry and Molecular method in detection of BRAF V600E mutation in papillary thyroid carcinoma
by: Sarah Ali Darweesh, et al.
Published: (2023-12-01)

BRAF<sup>V600E</sup> status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China
by: Zheng Xiangqian, et al.
Published: (2012-06-01)

BRAF non-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF V600E but without a survival advantage
by: Wei Wang, et al.
Published: (2021-05-01)

Role of Matrix Metalloproteinases and Their Inhibitors in Locally Invasive Papillary Thyroid Cancer
by: Irena Ivković, et al.
Published: (2022-12-01)

Radiomic Model for Determining the Value of Elasticity and Grayscale Ultrasound Diagnoses for Predicting BRAFV600E Mutations in Papillary Thyroid Carcinoma
by: Yu-guo Wang, et al.
Published: (2022-04-01)

Deep Small RNA Sequencing of BRAF V600E Mutated Papillary Thyroid Carcinoma With Lymph Node Metastasis
by: Azliana Mohamad Yusof, et al.
Published: (2019-10-01)

Role of contrast-enhanced ultrasound with time-intensity curve analysis about thyroid nodule and parenchyma for differentiating BRAF V600E mutation status
by: Zhipeng Hu, et al.
Published: (2025-02-01)

Developing Models to Predict <i>BRAF</i>V600E and <i>RAS</i> Mutational Status in Papillary Thyroid Carcinoma Using Clinicopathological Features and pERK1/2 Immunohistochemistry Expression
by: Agnes Stephanie Harahap, et al.
Published: (2023-10-01)

Case report: Metastatic BRAF V600E–mutated adult Wilms’ tumor with robust response to BRAF/MEK inhibitor therapy
by: Matthew R. Kroll, et al.
Published: (2024-07-01)

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
by: Priscilla Denise Zepeda-Lopez, et al.
Published: (2016-04-01)

Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non‐small cell lung cancer harboring BRAF V600E mutation: A case report
by: Zhicheng Huang, et al.
Published: (2024-08-01)

Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series
by: Danielle Pessôa-Pereira, et al.
Published: (2019-03-01)

Association of microRNA Expression and BRAF<sup>V600E</sup> Mutation with Recurrence of Thyroid Cancer
by: Daina Pamedytyte, et al.
Published: (2020-04-01)

Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer: Case Report
by: Shehab F. Mohamed, et al.
Published: (2019-12-01)

Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma
by: JIANG Jianyun, YING Hongmei
Published: (2022-05-01)

Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation
by: Ying Han, et al.
Published: (2022-06-01)

Implicaciones diagnósticas, terapéuticas y pronósticas de la mutación BRAF V600E en melanomas cutáneos
by: Alberto José Piamo Morales
Published: (2019-05-01)

Factors associated with BRAF V600E gene mutation in patients with undiagnosed papillary thyroid carcinoma by fine needle aspiration cytology
by: ZHANG Guozhi, et al.
Published: (2022-12-01)

Rethinking the role of oncogenes in papillary thyroid cancer initiation
by: Mario eVitale
Published: (2012-06-01)

CPSF30 at the Interface of Alternative Polyadenylation and Cellular Signaling in Plants
by: Manohar Chakrabarti, et al.
Published: (2015-06-01)